News
-
DDL 2024 drew the largest crowd ever in the 35-year history of the Drug Delivery to the Lung (DDL), with more than 100 OINDP experts attending online and approximately 1,000 attending in person at the… Read more . . .
-
Savara announced that it has initiated a rolling biologics license application submission for its Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company said that it will request priority review… Read more . . .
-
According to PureIMS, both the EMA and FDA have recently granted orphan drug designation to the company’s Colistin Cyclops dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients. Colistin Cyclops is… Read more . . .
-
Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo’s AmorphOX powder engineering technology and Abera’s vaccine platform, starting… Read more . . .
-
ARS Pharmaceuticals has announced that its partners in China, Japan, and Australia have all submitted marketing applications for approval of neffy epinephrine nasal spray for the treatment of serious allergic reactions in their respective countries. ARS is… Read more . . .
-
According to MannKind Corporation, the Indian Central Drugs Standard Control Organization (CDSCO) has approved a marketing application submitted by Cipla for Afrezza inhaled dry powder insulin for the treatment of diabetes in adults. Cipla acquired the… Read more . . .
-
Merxin Ltd and contract device manufacturer OECHSLERhealth have announced the formation of a strategic partnership called The SMI PowerHouse for manufacturing of Merxin’s MRX004 soft mist inhaler, a generic version of the Respimat device. According… Read more . . .
-
Intertek, which provides a wide range of testing services for OINDPs, has announced a new partnership with particle engineering specialist CrystecPharma for creation of a “fast to clinic” development platform for dry powder inhaler formulations.… Read more . . .
-
Qnovia announced that it has raised $16 million in Series B financing for development of its QN-01 nicotine inhaler for smoking cessation in the UK. In the US, the FDA recently approved Qnovia’s IND for… Read more . . .
-
CyanVac has announced the initiation of a Phase 2b clinical study of CVXGA intranasal COVID-19 vaccine shortly after the company announced results from its Phase 2a trial. The Phase 2b trial, which is expected to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA